Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 24 November 2014 | By Alexander Gaffney, RAC,
A new bill introduced in the US House of Representatives would grant existing pharmaceutical products an additional six months of marketing exclusivity if a company is able to demonstrate the product is able to treat or prevent a rare disease or condition.
The bill, the Orphan Product Extensions Now Accelerating Cures and Treatments Actof 2014 (OPEN ACT), appears to be loosely modeled off a similar plan in place for pediatric products. Under the US Food and Drug Administration's pediatric exclusivity provisions, sponsors are eligible to receive an additional six months of exclusivity if they provide data indicating their product is safe and effective in children.
The provisions, passed under the 1997 Food and Drug Administration Modernization Act (FDAMA), are meant to incentivize the development of safe and effective therapies for children. Notably, the six months of exclusivity applies (in most cases) to all approved indications for the drug, giving drug sponsors a powerful incentive to conduct studies. However, potential abuse of the program is limited by a requirement that FDA must first issue a pediatric written request (PRW) for the pediatric studies to be conducted.
For more, please read FDA's 1997 guidance document, Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug and Cosmetic Act.
The OPEN ACT operates on a similar concept, with some key differences.
Like the pediatric exclusivity provision, FDA would be permitted to extend a drug's exclusivity period by six months if a product—initially not approved as an orphan drug product—is later approved as such. Orphan drugs are those approved to treat rare conditions, defined as affecting fewer than 200,000 people in the US.
Unlike the pediatric provisions, the approval would have to be for an entirely new indication, and not just show the product works in a rare subset of the existing population.
In addition, FDA would not have to issue a written request for a company to be eligible for the added exclusivity.
The language appears to be of a substantial benefit for marketers of rare disease drugs. Some of those drug makers, such as Vertex Pharmaceuticals, have already adopted iterative drug development pipelines in which a single drug is tested (and approved) in multiple rare disease subsets. Under the OPEN ACT's language, marketing exclusivity for existing products could be extended by an additional six months.
The bill does not make clear if there is a limit to the number of six-month extensions a product is eligible for. OPEN ACT exclusivity would, however, be in addition to other types of exclusivity, such as pediatric exclusivity. However, FDA is to promulgate regulations on the extensions within two years of the bill's passage.
The bill applies to both drugs approved under Section 505 of the Federal Food, Drug and Cosmetics Act (FD&C Act) and biologics approved under Section 351(k) of the Public Health Service Act (PHSA).
Tags: OPEN ACT, Bill, Legislation, Congress, Orphan Drug, Exclusivity
Regulatory Focus newsletters
All the biggest regulatory news and happenings.